Skip to main content

Table 1 Clinicopathologic parameters according to adjuvant radiotherapy classification in Stage I patients of TCGA UCEC cohort

From: Integrating pathology, chromosomal instability and mutations for risk stratification in early-stage endometrioid endometrial carcinoma

Prognostic factors

Total

OB

VBT

EBRT

P

 

n = 294 (100%)

n= 123 (42%)

n = 92 (31%)

n= 79 (27%)

Agea

 Mean (range)

64 (31–90)

60 (31–89)

66 (35–90)

68 (35–87)

0.000

ANOVAb

 < 60

97 (33%)

65 (53%)

20 (22%)

12 (15%)

0.000

Pearson Chi2

 ≥ 60

195 (67%)

58 (47%)

71 (78%)

66 (85%)

  

Histologic type

    

0.000

Pearson Chi2

 Type I, EEC

250 (85%)

123 (100%)

92 (100%)

35 (44%)

  

 Type II, non-EEC

44 (15%)

0

0

44 (56%)

  

Grade

    

0.000

Pearson Chi2

 1

76 (26%)

66 (54%)

10 (11%)

0

  

 2

76 (26%)

57 (46%)

20 (22%)

1(1%)

  

 3

140 (48%)

0

62 (67%)

78 (99%)

  

Stagec

    

0.000

Pearson Chi2

 IA, MI < 50%

199 (68%)

105 (87%)

62 (67%)

32 (41%)

  

 IB, MI > 50%

92 (32%)

16 (13%)

30 (33%)

46 (59%)

  

CIN expression

 CIN25 Mean (range)

−0.03 (−1.45–3.24)

−0.41 (−1.45–2.38)

0.18 (−1.20–3.24)

0.54 (−1.29–2.23)

0.000

ANOVA

 CIN70 Mean (range)

−0.03 (−1.53–3.07)

−0.38 (−1.53–1.95)

0.17 (−1.09–3.07)

0.50 (−1.14–1.86)

0.000

ANOVA

Aneuploidy score

4.82 (0–31)

2.35 (0–20)

4.38 (0–27)

9.18 (0–31)

0.000

ANOVA

FGA

0.15 (0–0.95)

0.08 (0– 0.95)

0.15 (0–0.81)

0.25 (0–0.69)

0.000

ANOVA

Guidelines risk groupd

    

0.000

Pearson Chi2

 Low

105 (36%)

105 (87%)

0

0

  

 Intermediate

46 (16%)

16 (13%)

30 (33%)

0

  

 High-intermediate

62 (21%)

0

62 (67%)

0

  

 High

79 (27%)

0

0

79 (100%)

  

TCGA subtype

    

0.000

Pearson Chi2

 POLE-mutant

29 (10%)

12 (10%)

10 (11%)

7 (9%)

  

 MSI

99 (34%)

39 (32%)

37 (40%)

23 (29%)

  

 CNV Low

101 (34%)

67 (54%)

25 (27%)

9 (11%)

  

 CNV High

65 (22%)

5 (4%)

20 (22%)

40 (51%)

  

Mutation

  PTEN

223 (76%)

111 (90%)

73 (79%)

39 (49%)

0.000

Pearson Chi2

  FGFR2

59 (20%)

23 (19%)

22 (24%)

14 (18%)

n.s.

Pearson Chi2

  CTNNB1

72 (24%)

44 (36%)

22 (24%)

6 (8%)

0.000

Pearson Chi2

 PIK3CA

147 (50%)

67 (54%)

47 (51%)

33 (42%)

n.s.

Pearson Chi2

 PPP2R1A

40 (14%)

5 (4%)

12 (13%)

23 (29%)

0.000

Pearson Chi2

  1. aFor the two cases without age, one was in VBT group, another was in EBRT group
  2. bOne-way analysis of variance
  3. cFor the three cases without accurate MI, two were in OB group, one was in EBRT group
  4. dThere were two cases in OB group without complete clinicopathological information for guidelines risk assessment
Back to article page

Cell & Bioscience

ISSN: 2045-3701

Contact us